Article info
PDFPostScript
Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’
- Correspondence to Dr Thomas Botton, Team 1, INSERM U1065, Nice 06204, France; thomas.botton{at}unice.fr
Citation
Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’
Publication history
- Received December 6, 2019
- Accepted December 9, 2019
- First published December 18, 2019.
Online issue publication
July 20, 2020
Article Versions
- Previous version (18 December 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.